《Biomarker Research》雜志的最新年發文量為84篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在醫學：研究與實驗領域的學術影響力。
該刊聚焦于醫學-醫學：研究與實驗領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 10 Weeks 。
Biomarker Research 雜志發文統計
文章名稱引用次數
- Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential48
- Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm43
- Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy37
- Isocitrate dehydrogenase inhibitors in acute myeloid leukemia17
- Novel insights into MSC-EVs therapy for immune diseases14
- Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia14
- Epigenetic heterogeneity in cancer13
- Mesothelin as a biomarker for targeted therapy12
- Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer10
- Molecular landscape and targeted therapy of acute myeloid leukemia10
國家/地區發文量
- CHINA MAINLAND78
- USA40
- GERMANY (FED REP GER)9
- Sweden6
- Australia5
- France5
- Japan5
- Canada4
- England4
- Belgium2
